RxDoctor Payments Data

Joshua Nathan, MD

Obstetrics & Gynecology · Manchester, NHNPI 1972605962

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2024 at $102 and has fallen 83.7% since, to $17 in 2025.

$380in general payments, 2019–2025

Across 18 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$134
  • Exeltis, USA Inc.$50
  • Gynesonics, Inc.$49
  • Evofem Biosciences, Inc.$39
  • Organon$32
  • Myovant Sciences Inc.$30
  • plus $47 from 3 others
$100in research payments, 2019–2025

Across 1 payment — averaging $100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$100

What the payments were for

  • Food & beverage$380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$380 in reported general payments places this provider in the 75th percentile of 186 obstetrics & gynecology providers in New Hampshire.

See all obstetrics & gynecology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$16,740
Medicare patients
82
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol18$1,357
Clobetasol Propionate18$558

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →